The US FDA convened five advisory committee meetings to discuss NMEs and novel biologics during the first half of the year. Two of the meetings took place after the user fee goal date had passed, suggesting the value that the FDA places on scientific advice for challenging applications.
While the agency is not bound by the recommendations of its advisory committees, it does consistently agree with them. Indeed,...





